Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 7/20 | 0.44 |
| ▸ | MAOA | P21397 | 6/20 | 0.44 |
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9989762 | 1.00 | MAPT (0.55) | MAPTPOLBKDM1AMAOAMAOB | |
| SCHEMBL2528047 | 0.93 | MAPT (0.52) | MAPTPOLBKDM1AMAOAMAOB | |
| SCHEMBL12035589 | 0.93 | MAPT (0.52) | MAPTPOLBKDM1AMAOAMAOB | |
| SCHEMBL28885404 | 0.84 | TUBB4A (0.44) | MAPTCYP2C19MEN1KMT2A | |
| SCHEMBL19612364 | 0.83 | MAPT (0.49) | MAPTPOLBMAPK1CYP2C19MEN1 | |
| SCHEMBL28885344 | 0.83 | KDM4E (0.42) | MAPTPOLBKDM1AMAPK1MEN1 | |
| SCHEMBL28279217 | 0.83 | OPRK1 (0.47) | MAPTKDM1A | |
| SCHEMBL28885346 | 0.83 | KDM1A (0.41) | MAPTKDM1ASMN1; SMN2 | |
| SCHEMBL28885394 | 0.82 | OPRK1 (0.50) | MAPTCYP2C19MEN1KMT2AGAA | |
| SCHEMBL28558069 | 0.81 | SMN1; SMN2 (0.56) | KDM1AMAOAMAOBHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9024093-B2 | Fluorination of organic compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-05-05 | — | — | US | disclosed |
| US-20110312903-A1 | FLUORINATION OF ORGANIC COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2011-12-22 | — | — | US | disclosed |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| US-7109343-B2 | Metal catalysts and methods for making and using same | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050010049-A1 | Metal catalysts and methods for making and using same | DAVIES HUW M L (US) | 2005-01-13 | — | — | US | disclosed |
| US-6762304-B2 | BIS-TRANSITION METAL CATALYSTS HAVING D2 SYMMETRY | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2004-07-13 | — | — | US | disclosed |
| EP-1173278-B1 | METAL CATALYSTS AND METHODS FOR MAKING AND USING SAME | RES FOUNDATION OFSTATE UNIVERS (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20020183535-A1 | Metal catalysts and methods for making and using same | DAVIES HUW M L (US) | 2002-12-05 | — | — | US | disclosed |
| US-6410746-B1 | ORGANOMETALLIC COMPOUND CONTAINING TRANSITION METAL | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183535-A1 | Metal catalysts and methods for making and using same | COMT, SLC6A3, SLC6A2 | MAPT 2849/4885POLB 1252/4885KDM1A 2630/4885 |
| US-20110312903-A1 | FLUORINATION OF ORGANIC COMPOUNDS | SLCO1B3, SLCO2B1, FLI1 | MAPT 2278/4885POLB 471/4885KDM1A 3707/4885 |
| US-20050010049-A1 | Metal catalysts and methods for making and using same | SLC6A3, COMT, DRD4 | MAPT 1443/4885POLB 2171/4885KDM1A 2806/4885 |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | HTR2C, HTR2A, HTR5A | MAPT 4271/4885POLB 4713/4885KDM1A 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.